share_log

Philippine Drug Regulator Approves Jiangsu Recbio's Clinical Trial for Shingles Vaccine; Shares Slip 8%

Philippine Drug Regulator Approves Jiangsu Recbio's Clinical Trial for Shingles Vaccine; Shares Slip 8%

菲律賓藥品監管機構批准江蘇 Recbio 針對帶狀皰疹疫苗的臨床試驗;股價下滑 8%
MT Newswires ·  2022/12/19 02:48

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論